Funding combines equity investment and convertible loanFocus on best-in-class, clinical-stage peanut allergen neutralizing antibody Further potential for developing Mabylon’s discovery and ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Good afternoon, and welcome to the Relmada Therapeutics Second ...

Researchers with the schools of science and engineering at Rensselaer Polytechnic Institute (RPI) are exploring new ways to ...

DelveInsight's, “Advanced Hepatocellular Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 50+ ...

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...

Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential ...

Researchers with the schools of science and engineering at Rensselaer Polytechnic Institute (RPI) are exploring new ways to manipulate matter with light to unlock a new generation of computer chips, ...

This initiative showcases real electricians sharing practical tips and behind-the-scenes insights, helping to elevate the ...

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...

An example of how EY has deployed AI is in its tax business – for which EY is Singapore and Asean’s largest player. In March ...